Recently, Nie et al. revealed that the YAP/TAZ-CD54 axis was required for CXCR2−CD44− tumor-specific neutrophils to suppress gastric cancer, opening a new possibility to develop neutrophil-based antitumor therapeutics [139]. The gene discussed is YAP1; the disease is neoplasm.